Quick Answer
Centessa Pharmaceuticals plc reported Net Income Loss of -$197.53 million for the year ending 2025.
- Centessa Pharmaceuticals plc showed an increase of +16.2% in Net Income Loss from 2024 to 2025.
- This data is from Centessa Pharmaceuticals plc's annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2019 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2019 to 2025), Centessa Pharmaceuticals plc's Net Income Loss has declined by 3,803.0%.
- Historical annual values: Fiscal year 2025: -$197.53 million | Fiscal year 2024: -$235.76 million | Fiscal year 2023: -$151.09 million | Fiscal year 2022: -$216.21 million | Fiscal year 2021: -$381.07 million | Fiscal year 2021: -$829.0 thousand | Fiscal year 2020: -$10.66 million | Fiscal year 2019: -$5.06 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: